News & Events
  • We Offer

    Florentis offers services in custom synthesis, asymmetric synthesis, process development, analytical services and reference standards of drug intermediates, APIs, impurities and metabolites.

Dr. Shriram Kotkar
Managing Director

Dr. Kotkar received his Ph.D. in Organic Chemistry in 2007 under the supervision of Dr. A. Sudalai, from National Chemical Laboratory (NCL) Pune, India. His doctoral studies consist of development of organocatalytic asymmetric synthetic methods and their implementation for the enantiopure synthesis of various chiral drugs such as anti-tuberculosis drug (S,S) Ethambutol, anti-epileptic agent (S)-Levetiracetam, anti-hypertensive drug (S)-α-Methyldopa, (S)- Cericlamine, (-)- Anisomycin, (R)- Hexanolide, (R, R)-Harzialactone A, etc. He is an Alexander von Humboldt fellow, where he worked about three years as a postdoctoral researcher in the research group of Dr. Maja Koehn at European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. His postdoctoral studies include synthesis of complex inositol derivatives and development of novel synthetic route for phosphoinositides on solid support. He has over a decade of experience in the field of synthetic Organic Chemistry and has 7 publications to his credit.

Dr. Laxman Malge

Dr. Malge received his Ph. D. in Organic Chemistry in 2010 from the Department of Chemistry, Technical University of Munich, Germany, under the supervision of Prof. Dr. F. P. Schmidtchen. His doctoral research mainly involved design and synthesis of both water soluble artificial receptors based on bicyclic guanidinium anchor group as well as phosphinate guests. This project facilitated him to learn multi-step organic synthesis involving palladium catalyzed cross-coupling reactions, hydroboration, phosphate-phosphinate rearrangement, RCM, etc., to prepare Nitrogen, Sulphur and Phosphorus containing heterocyclic compounds. He was a Research Associate in Emcure Pharmaceuticals Ltd., Pune and was actively involved in the synthesis of chiral drugs and supervised its successful execution at Kilo-laboratory and pilot plant. As a Chemist at Asian paints India Ltd., Mumbai, he designed and developed new products such as hygiene coatings and provided technical support to the plants in successful production. Overall he has a decade of research experience in Industry and Academia.

Dr. Vijaykumar Pawar

Dr. Pawar received his Ph.D. in Organic Chemistry in 2006 from KULeuven, Belgium. His doctoral studies include synthesis of peptides and peptidomimetics as well as development of methodologies for novel heterocyclic molecules such as pyrazinones and imidazole derivatives. As a postdoctoral researcher at Chemical Genomics Center of the Max Planck Society, Dortmund, Germany he worked on several multidisciplinary projects on small molecule kinase inhibitors (derived from quinoline, quinazoline, thiazole and flavone) and their use in basic cancer research. Interestingly, the new quinoline analogue showed higher activity against an important EGFR mutant, EGFR-858R, T790M, than its marketed counterpart Erlotinib (Tarceva). At Purdue University, USA he worked on Design and synthesis of inhibitors and mechanism probes for riboflavin synthase and lumazine synthase. Dr. Pawar has more than 11 years of experience in the field of Organic Chemistry, Medicinal Chemistry and subjects at the interface of chemistry and biology. He has more than 15 international publications including patents to his credit.